Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment

Rudi Hwang, Takahiro Shinkai, Vincenzo Deluca, Fabio Macciardi, Steven Potkin, Herbert Y. Meltzer, James L. Kennedy*

*Corresponding author for this work

Research output: Contribution to journalArticle

38 Scopus citations

Abstract

Objective: Explore relationships between 12 dopamine D2 gene variants and quantitative measures of positive and negative symptom response following clozapine treatment in two treatment refractory or intolerant populations (Caucasian and African-American). Experimental procedures: Subjects included 97 Caucasian and 35 African-American DSM-III-R or DSM-IV schizophrenics and were genotyped by 5′-exonuclease fluorescence assays. Genotype, allele +/- and haplotype groups were compared on Brief Psychiatric Rating Scale (BPRS) overall, positive (BPOS) and negative symptom subscales (BNEG) using analysis of variance. Results: In Caucasians, no significant associations were found for any individual polymorphisms or haplotypes. In African-Americans, the TaqIB B2 (T) allele and rs1125394 allele 1 (A), and a two-marker haplotype containing these two alleles were associated with improvement in overall BPRS and BPOS response. Conclusions: Variability in clozapine response is still not fully understood and likely involves multiple factors. This study suggests that D2 receptor gene variants may be among such factors.

Original languageEnglish (US)
Pages (from-to)248-259
Number of pages12
JournalEuropean Neuropsychopharmacology
Volume16
Issue number4
DOIs
StatePublished - May 1 2006

Keywords

  • Antipsychotics
  • Clozapine
  • D2
  • Dopamine
  • Pharmacogenetics
  • Response

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment'. Together they form a unique fingerprint.

  • Cite this